Boston Scientific (BSX) AGM 2026 summary

Opening remarks and agenda

• Meeting held virtually to engage stockholders globally, with agenda and rules posted online.

• Voting instructions and Q&A procedures explained at the outset.

• Safe harbor reminder for forward-looking statements provided.

Board and executive committee updates

• Board members standing for re-election introduced, including notable industry leaders.

• Two long-serving board members, Yoshiaki Fujimori and John Sununu, retired and were acknowledged for their service.

• Ernst & Young representatives present as independent auditors.

Financial performance review

• Achieved $20 billion in net sales for 2025, with mid-teens growth rate.

• Over $2 billion invested in R&D, expanding reach to 127 countries and treating over 48 million patients.

• Venture capital portfolio includes 45+ active investments, supporting pipeline and future acquisitions.